Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Live updates

1. 2h ago

   Eli Lilly combo drug EloraTZP beats tirzepatide in mid-stage trial

   Eli Lilly reported that EloraTZP, a combination of tirzepatide and the experimental amylin drug eloralintide, outperformed tirzepatide 15 mg in a 48-week Phase 2 trial. The study involved adults with obesity and type 2 diabetes, showing that patients lost an average of 23.3% of their body weight and saw improved A1C reduction compared to tirzepatide alone. Following these positive results, the company intends to launch Phase 3 trials for the combination regimen by the end of 2026.

   Why it matters

   The obesity market is highly competitive, with Eli Lilly and Novo Nordisk facing new challenges from Roche's experimental drug enicepatide. Lilly is also developing retatrutide, another potent weight-loss candidate. These efforts aim to establish a new high-water mark for efficacy in weight reduction and metabolic health.

   What is confirmed

   • EloraTZP is a combination of the drug tirzepatide and the experimental amylin drug eloralintide.
   • In a 48-week Phase 2 trial, EloraTZP delivered greater weight loss and A1C reduction than tirzepatide 15 mg in adults with obesity and type 2 diabetes.
   • Patients using EloraTZP lost an average of 23.3% of their body weight.
   • Eli Lilly plans to start Phase 3 trials for the eloralintide and tirzepatide combo by the end of the year.
   • Roche's experimental drug enicepatide helped overweight or obese patients with type 2 diabetes lose an average of 15.5% of their body weight in a mid-stage trial.

   Still unconfirmed

   • Some patients using an emerging drug lost up to a quarter of their body weight.
   • People with type 2 diabetes lost up to 60 pounds on Lilly's latest weight loss drug.
   • Lilly's retatrutide GLP-1 delivers an average weight loss of 50 pounds.

   What to watch next

   • Launch of Phase 3 trials for EloraTZP at the end of 2026
   • Release of full Phase 3 data for retatrutide
   Sources used for this update (20)

   1. finance.yahoo.com — Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?
   2. Ars Technica — Most powerful obesity drug yet: People lost up to 25% of weight in trial
   3. The Guardian — ‘Godzilla’ of weight-loss drugs could provide other important health benefits
   4. Reuters — Lilly's experimental drug cuts weight by 21% in diabetes trial
   5. Scientific American — Blockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs
   6. NBC News — People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug
   7. Fierce Biotech — Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
   8. CNBC — Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
   9. Eli Lilly — Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
   10. USA Today — Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds
   11. Fierce Biotech — Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
   12. Yahoo — Emerging drug helps some patients lose up to quarter of body weight
   confidence 100%